Brainreader

Brainreader operates at the intersection of clinical decision support, medical imaging software, and neurodegenerative disease diagnostics. Its core product, Neuroreader®, is FDA-cleared and CE-marked software that converts structural MRI scans into quantitative brain-volume measurements, targeting neurologists, radiologists, imaging centers, and researchers. The company’s differentiation is its focus on automated volumetrics and longitudinal monitoring rather than image viewing alone: the platform is described as analyzing more than 65 brain structures in under 10 minutes, while its product record specifies quantification of 45 structures. That discrepancy should be clarified, but both figures indicate a broad structural-analysis workflow. Its positioning is strengthened by regulatory clearances, HIPAA compliance, clinical-market orientation, and integration with INFINITT PACS. The May 2026 Lovell partnership expands access to U.S. federal buyers, potentially improving distribution. However, the company remains small, with an employee range of one to ten, and public information provides limited evidence on market share, recurring revenue, or comparative clinical outcomes.

Brainreader’s trajectory shows a long transition from university-originated research to commercial clinical software. Founded in 2011 as an Aarhus University spin-off, the company raised DKK 11 million, converted to approximately $1.64 million, in a 2019 seed round involving CBC Investment Group, Investo Capital, and Bevica Innovation A / S. Its next disclosed financing came on May 28, 2025, when it raised $7.3 million led by Dahlgren Capital, increasing cumulative disclosed funding to $8.94 million. That funding appears to mark the clearest scaling inflection point, supporting new clinical applications and broader market reach. The commercial organization then expanded through Steve Green’s appointment as Head of U.S. Sales in December 2025 and Cyrus A. Raji, MD, PhD joining as Chief Medical Officer in January 2026. The May 2026 agreement with Lovell Government Services created a route into VA, DoD, and Indian Health Service facilities through the GSA MAS. Product-wise, Neuroreader® provides automated MRI volumetrics, longitudinal tracking, and clinical decision support. Growth remains difficult to quantify because employee data still indicates a one-to-ten-person company and no revenue, deployment, or customer-count metrics are publicly available.